The engineered T cells were cultivated with primary AML cells (n = 6) at E:T = 1:50 ratio; after 7 days, the percentages of live AML targets and effector EGFR+ T cells were measured by FACS with antibodies specific to the antigens CD123, CD3, and EGFR. This evidence concerns the gene EGFR and acute myeloid leukemia.